---
title: "Dupixent (dupilumab) in atopic dermatitis: Clinical trials questions"
description: "Clinical trials questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: SOLO 1 and SOLO 2, CHRONOS, Itch relief, Maintenance of response, Skin barrier, Pediatric efficacy, and 3 further topics. Questions: How effective is Dupixent alone for adults with atopic dermatitis (SOLO 1 and SOLO 2)? How effective is Dupixent with topical corticosteroids in adults at 16 weeks (CHRONOS)? What are the 1-year Dupixent results in adults with atopic dermatitis (CHRONOS)? How fast does Dupixent relieve atopic dermatitis itch in adults (post hoc analysis)? 13 further questions follow. 17 questions quoted from 9 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Clinical trials questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## SOLO 1 and SOLO 2

<a id="dupixent-solo-monotherapy"></a>

### How effective is Dupixent alone for adults with atopic dermatitis (SOLO 1 and SOLO 2)?

> “At Week 16 in the parent studies (SOLO 1 and SOLO 2)<sup>1,5</sup>:
>
> EASI-75 was achieved by 51% and 44% of patients treated with DUPIXENT vs 15% and 12% with placebo in SOLO 1 and SOLO 2, respectively (secondary endpoint; P<0.001)
> Clear or almost-clear skin was achieved by 38% and 36% of patients treated with DUPIXENT vs 10% and 9% with placebo in SOLO 1 and SOLO 2, respectively (primary endpoint; P<0.001)”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=At%20Week%2016%20in%20the,2%2C%20respectively%20%28primary%20endpoint%3B%20P%3C0.001%29)

> “41%
>
> of adults treated with DUPIXENT (n=213) achieved ≥4-point reduction in Peak Pruritus NRS vs 12% with placebo at Week 16 in SOLO 1 (n=212; P<0.001)
>
> 36%
>
> of adults treated with DUPIXENT (n=225) achieved ≥4-point reduction in Peak Pruritus NRS vs 10% with placebo at Week 16 in SOLO 2 (n=221; P<0.001)”

Source: [DUPIXENT: Adult Pruritus NRS Efficacy Results, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pruritus-nrs-clinical-trial#:~:text=41%25,in%20SOLO%202%20%28n%3D221%3B%20P%3C0.001%29)

> “CHRONOS, SOLO 1, and SOLO 2 enrolled adult subjects. In these trials, disease severity at baseline was defined by an IGA score of ≥3 in the overall assessment of AD lesions on a severity scale of 0 (clear) to 4 (severe); an EASI score of ≥16 on a scale of 0 to 72; and a minimum BSA involvement of ≥10%. At baseline, 52% of subjects had an IGA score of 3 (moderate); 48% had an IGA of 4 (severe); mean EASI score was 33; weekly averaged Peak Pruritus NRS was 7 on a scale of 0 to 10. Mean disease duration was ≈28 years and mean age was 38 years.<sup>1,4</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Efficacy Results for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety#:~:text=CHRONOS%2C%20SOLO%201%2C%20and%20SOLO,and%20mean%20age%20was%2038)

> “In CHRONOS, SOLO 1, and SOLO 2, a loading dose of 600 mg (2 x 300 mg SC injections) was followed by 300 mg (1 SC injection) Q2W.<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Efficacy Results for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety#:~:text=In%20CHRONOS%2C%20SOLO%201%2C%20and,300%20mg%20%281%20SC%20injection%29)

> “Table 18: 
> Efficacy Results of DUPIXENT with or without Concomitant TCS at Week 
> 16 (FAS) in Adult Subjects with Moderate-to-Severe AD 
>
> SOLO 1  
> SOLO 2 
> CHRONOS 
>
> DUPIXENT 
> 300 mg Q2W 
> Placebo 
>
> DUPIXENT 
> 300 mg 
> Q2W 
> Placebo 
>
> DUPIXENT  
> 300 mg Q2W 
> + TCS 
> Placebo 
> + TCS 
>
> Number of subjects 
> randomized (FAS)<sup>a</sup> 
> 224 
> 224 
> 233 
> 236 
> 106 
> 315 
> IGA 0 or 1<sup>b,c</sup>  
> 38% 
> 10% 
> 36% 
> 9% 
> 39% 
> 12% 
> EASI-75<sup>c</sup> 
> 51% 
> 15% 
> 44% 
> 12% 
> 69% 
> 23% 
> EASI-90<sup>c</sup> 
> 36% 
> 8% 
> 30% 
> 7% 
> 40% 
> 11% 
> Number of subjects with 
> baseline Peak Pruritus 
> NRS score ≥4 
> 213 
> 212 
> 225 
> 221 
> 102 
> 299 
> Peak Pruritus NRS  
> (≥4-point improvement)<sup>c</sup>  
> 41% 
> 12% 
> 36% 
> 10% 
> 59% 
> 20% 
> <sup>a</sup> Full Analysis Set (FAS) includes all subjects randomized. 
> <sup>b</sup> Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”) and a reduction of ≥2 points on 
> a 0-4 IGA scale. 
> <sup>c</sup> Subjects who received rescue treatment or with missing data were considered as non-responders.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 38, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=38)

## CHRONOS

<a id="dupixent-chronos-week16"></a>

### How effective is Dupixent with topical corticosteroids in adults at 16 weeks (CHRONOS)?

> “At Week 16 in CHRONOS, 69% of adults treated with DUPIXENT + TCS (n=106) achieved EASI-75 vs 23% with placebo + TCS (n=315; secondary endpoint; P<0.0001)<sup>1,2,с</sup>
> At Week 16 in CHRONOS, 39% of adults treated with DUPIXENT + TCS achieved clear or almost-clear skin (IGA 0 or 1 and ≥2 point improvement) vs 12% with placebo + TCS (primary endpoint; P<0.0001)<sup>1,2,с</sup>”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=At%20Week%2016%20in%20CHRONOS%2C,placebo%20%2B%20TCS%20%28primary%20endpoint%3B)

> “At Week 16 in CHRONOS, 59% of adults treated with DUPIXENT + TCS (n=102) achieved a significant itch reduction vs 20% with placebo + TCS (n=299; secondary endpoint; P<0.0001)<sup>1,3,с</sup>”

Source: [DUPIXENT: Adult Pruritus NRS Efficacy Results, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pruritus-nrs-clinical-trial#:~:text=At%20Week%2016%20in%20CHRONOS%2C,%2B%20TCS%20%28n%3D299%3B%20secondary%20endpoint%3B)

> “In CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=In%20CHRONOS%2C%20as%20needed%2C%20subjects,and%20intertriginous%20and%20genital%20areas.)

<a id="dupixent-chronos-week52"></a>

### What are the 1-year Dupixent results in adults with atopic dermatitis (CHRONOS)?

> “In CHRONOS, of the 421 subjects, 353 had been on study for 52 weeks at the time of data 
> analysis. Of these 353 subjects, responders at Week 52 represent a mixture of subjects who 
> maintained their efficacy from Week 16 (e.g., 53% of DUPIXENT IGA 0 or 1 responders at 
> Week 16 remained responders at Week 52) and subjects who were non-responders at Week 16 
> who later responded to treatment (e.g., 24% of DUPIXENT IGA 0 or 1 non-responders at 
> Week 16 became responders at Week 52). Results of supportive analyses of the 353 subjects in 
> the DUPIXENT with concomitant TCS trial (CHRONOS) are presented in Table 19. 
> Table 19: 
> Efficacy Results (IGA 0 or 1) of DUPIXENT with Concomitant TCS at Week 
> 16 and 52 in Adult Subjects with Moderate-to-Severe AD 
>
> DUPIXENT 
> 300 mg Q2W + TCS 
> Placebo + TCS 
> Number of Subjects<sup>a</sup> 
> 89 
> 264 
> Responder<sup>b,c</sup> at Week 16 and 52 
> 22% 
> 7% 
> Responder at Week 16 but Non-responder at Week 52 
> 20% 
> 7% 
> Non-responder at Week 16 and Responder at Week 52 
> 13% 
> 6% 
> Non-responder at Week 16 and 52 
> 44% 
> 80% 
> Overall Responder<sup>b,c</sup> Rate at Week 52 
> 36% 
> 13% 
> <sup>a</sup> In CHRONOS, of the 421 randomized and treated subjects, 68 subjects (16%) had not been on study for 52 weeks 
> at the time of data analysis. 
> <sup>b</sup> Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”) and a reduction of ≥2 points on 
> a 0-4 IGA scale. 
> <sup>c</sup> Subjects who received rescue treatment or with missing data were considered as non-responders.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 39, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=39)

> “Proportion of patients with ≥4-point reduction in Peak Pruritus NRS: 51% with DUPIXENT + TCS vs 13% with placebo + TCS; P<0.0001, secondary endpoint<sup>1,2</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Efficacy Results for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety#:~:text=Proportion%20of%20patients%20with%20%E2%89%A54%2Dpoint,placebo%20%2B%20TCS%3B%20P%3C0.0001%2C%20secondary)

> “Proportion of patients achieving EASI-75: 65% with DUPIXENT + TCS vs 22% with placebo + TCS; P<0.0001, secondary endpoint<sup>1,2</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Efficacy Results for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety#:~:text=Proportion%20of%20patients%20achieving%20EASI%2D75%3A,placebo%20%2B%20TCS%3B%20P%3C0.0001%2C%20secondary)

> “DUPIXENT 300 mg Q2W + TCS (n=89)
> Placebo + TCS (n=264)”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=DUPIXENT%20300%20mg%20Q2W%20%2B,Placebo%20%2B%20TCS%20%28n%3D264%29)

> “DUPIXENT 300 mg Q2W + TCS (n=86)
> Placebo + TCS (n=249)”

Source: [DUPIXENT: Adult Pruritus NRS Efficacy Results, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pruritus-nrs-clinical-trial#:~:text=DUPIXENT%20300%20mg%20Q2W%20%2B,Placebo%20%2B%20TCS%20%28n%3D249%29)

> “Week 52 data were limited to patients completing 52 weeks as of the cutoff date.”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=Week%2052%20data%20were%20limited,as%20of%20the%20cutoff%20date.)

Note: The n values are the chart legends for the Week 52 EASI-75 analysis (skin clearance page) and the Week 52 itch analysis (itch page).

## Itch relief

<a id="dupixent-itch-onset"></a>

### How fast does Dupixent relieve atopic dermatitis itch in adults (post hoc analysis)?

> “Decrease in daily Peak Pruritus NRS from baseline in adults starting at Day 2 with DUPIXENT monotherapy<sup>5,a</sup>
>
> Change in daily Peak Pruritus NRS from baseline in a post hoc analysis of pooled SOLO 1 and SOLO 2 trials (−4.5% with DUPIXENT [n=457] vs −0.6% with placebo [n=460]).
>
> Definitive conclusions cannot be made as this was a post hoc analysis in which data were not multiplicity controlled and P value was nominal.”

Source: [DUPIXENT: Adult Pruritus NRS Efficacy Results, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pruritus-nrs-clinical-trial#:~:text=Decrease%20in%20daily%20Peak%20Pruritus,and%20P%20value%20was%20nominal.)

> “Pooled analysis of SOLO 1 and SOLO 2 (N=1379); ≥4-point improvement was seen at Day 4 in adult patients receiving Q2W dosing of DUPIXENT.”

Source: [DUPIXENT: Adult Pruritus NRS Efficacy Results, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pruritus-nrs-clinical-trial#:~:text=Pooled%20analysis%20of%20SOLO%201,receiving%20Q2W%20dosing%20of%20DUPIXENT.)

## Maintenance of response

<a id="dupixent-solo-continue"></a>

### Does Dupixent keep working if adults continue it after 16 weeks (SOLO-CONTINUE)?

> “Subjects in SOLO 1 and SOLO 2 who had an IGA 0 or 1 with a reduction of ≥2 points were re-
> randomized into SOLO CONTINUE (NCT02395133). SOLO CONTINUE evaluated multiple 
> DUPIXENT monotherapy dose regimens for maintaining treatment response. The study included 
> subjects randomized to continue with DUPIXENT 300 mg Q2W (62 subjects) or switch to 
> placebo (31 subjects) for 36 weeks. IGA 0 or 1 responses at Week 36 were as follows: 33 (53%) 
> in the Q2W group and 3 (10%) in the placebo group.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 39, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=39)

> “SOLO-CONTINUE STUDY DESIGN: At the end of SOLO 1 and SOLO 2 (week 16), adult patients achieving IGA 0 or 1 and/or EASI-75 could enroll in SOLO CONTINUE, a double-blind phase 3 study. Patients who received rescue treatment in SOLO 1 and SOLO 2 (including TCS/TCI) were considered nonresponders. Patients who received DUPIXENT 300 mg Q2W in either parent study were randomized to DUPIXENT 300 mg Q2W (n=80), DUPIXENT 300 mg Q4W (n=41), DUPIXENT 300 mg Q8W (n=39), or placebo (n=39).<sup>4</sup>
> Limitation of analysis: Rescue medication use does not directly capture the presence, severity, or duration of a flare. Only Week 16 responders were eligible to enroll. SOLO-CONTINUE duration was 36 weeks.<sup>4</sup>”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=SOLO%2DCONTINUE%20STUDY%20DESIGN%3A%20At%20the,enroll.%20SOLO%2DCONTINUE%20duration%20was%2036)

Note: The page also charts the proportion of patients with no flares through Week 52 in a post hoc analysis; those chart values are not quoted here.

## Skin barrier

<a id="dupixent-skin-barrier"></a>

### Does Dupixent improve skin barrier function in atopic dermatitis?

> “Data from an open-label exploratory study measuring skin barrier function<sup>6</sup>”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=Data%20from%20an%20open%2Dlabel%20exploratory%20study%20measuring%20skin%20barrier)

> “At baseline, median TEWL in AD lesional skin was significantly greater vs healthy skin<sup>6</sup>
> At Week 16, no difference observed between AD lesional skin and healthy skin<sup>6</sup>”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=At%20baseline%2C%20median%20TEWL%20in,AD%20lesional%20skin%20and%20healthy)

> “BALISTAD: 52 subjects were enrolled in this open-label study, with 26 participants enrolled into the moderate-to-severe AD cohort and the healthy volunteer cohort. Adult AD subjects and adolescent (aged 12-17 years) AD subjects weighing ≥60 kg received a loading dose of DUPIXENT 600 mg followed by 300 mg Q2W through Week 14. Adolescents weighing <60 kg received a loading dose of DUPIXENT 400 mg followed by 200 mg Q2W through Week 14. Healthy volunteers were age and gender-matched with AD subjects and did not receive any treatment. TEWL was compared before and after 5 skin tape-stripping measurements.<sup>7</sup>”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=BALISTAD%3A%2052%20subjects%20were%20enrolled,and%20after%205%20skin%20tape%2Dstripping)

> “Similar results were also observed in children aged 6-11 years<sup>7</sup>
>
> At baseline, mean TEWL in AD lesional skin was significantly greater vs healthy skin. At Week 16 and Week 28, no difference observed between AD lesional skin and healthy skin.”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=Similar%20results%20were%20also%20observed,lesional%20skin%20and%20healthy%20skin.)

> “PELISTAD: Open-label, exploratory study on skin barrier function in 41 children aged 6 to 11 years. Subjects were moderate-to-severe AD patients (n=23) or matched healthy volunteers (n=18). AD subjects were treated with DUPIXENT for up to 16 weeks (with post-treatment follow-up at Week 28). AD subjects weighing 15 kg to <30 kg received a loading dose of DUPIXENT 600 mg followed by 300 mg Q4W, and subjects weighing 30 kg to <60 kg received a loading dose of DUPIXENT 400 mg followed by 200 mg Q2W. TEWL was compared before and after up to 20 skin tape-stripping measurements.<sup>7</sup>”

Source: [DUPIXENT: Adult Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-clearance-data#:~:text=PELISTAD%3A%20Open%2Dlabel%2C%20exploratory%20study%20on,up%20to%2020%20skin%20tape%2Dstripping)

## Pediatric efficacy

<a id="dupixent-pediatric-clear-skin"></a>

### What percentage of children on Dupixent for atopic dermatitis reach clear or almost-clear skin?

> “At Week 16 in pivotal trials, pediatric patients achieving the primary endpoint of IGA 0 (clear) or 1 (almost clear), and in adolescents ≥2-point improvement, were as follows: infants to preschoolers (6 months to 5 years): 28% receiving DUPIXENT 200/300 mg Q4W + TCS (n=83) vs 4% receiving placebo + TCS (n=79; P<0.0001); children (6–11 years) weighing <30 kg: 30% receiving DUPIXENT 300 mg Q4W + TCS (n=61) vs 13% receiving placebo + TCS (n=61); children (6–11 years) weighing ≥30 kg: 39% receiving DUPIXENT 200 mg Q2W + TCS (n=59) vs 10% receiving placebo + TCS (n=62); adolescents (12–17 years): 24% receiving DUPIXENT 200/300 mg Q2W (n=82) vs 2% receiving placebo (n=85; P<0.001)<sup>1-4,a,b</sup>”

Source: [DUPIXENT: Pediatric Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-skin-clearance-data#:~:text=At%20Week%2016%20in%20pivotal,vs%202%25%20receiving%20placebo%20%28n%3D85%3B)

> “The results present are not intended to be comparative across clinical trials.”

Source: [DUPIXENT: Pediatric Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-skin-clearance-data#:~:text=The%20results%20present%20are%20not%20intended%20to%20be%20comparative%20across%20clinical%20trials.)

> “Full analysis set includes all subjects randomized.<sup>1</sup>”

Source: [DUPIXENT: Pediatric Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-skin-clearance-data#:~:text=Full%20analysis%20set%20includes%20all%20subjects)

> “In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.<sup>1</sup>”

Source: [DUPIXENT: Pediatric Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-skin-clearance-data#:~:text=In%20the%20primary%20analyses%20of,with%20missing%20data%20were%20considered)

<a id="dupixent-adolescent-ad1526"></a>

### How effective is Dupixent in adolescents with atopic dermatitis (AD-1526)?

> “The efficacy of DUPIXENT monotherapy in pediatric subjects 12 years of age and older was 
> evaluated in a multicenter, randomized, double-blind, placebo-controlled trial (AD-1526; 
> NCT03054428) in 251 pediatric subjects 12 to 17 years of age, with moderate-to-severe AD 
> defined by an IGA score ≥3 (scale of 0 to 4), an EASI score ≥16 (scale of 0 to 72), and a 
> minimum BSA involvement of ≥10%. Eligible subjects enrolled into this trial had previous 
> inadequate response to topical medication.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 39, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=39)

> “In AD-1526, the mean age was 14.5 years, the median weight was 59.4 kg, 41% of subjects were 
> female, 63% were White, 15% were Asian, and 12% were Black. At baseline, 46% of subjects 
> had an IGA score of 3 (moderate AD), 54% had an IGA score of 4 (severe AD), the mean BSA 
> involvement was 57%, and 42% had received prior systemic immunosuppressants. Also, at 
> baseline, the mean EASI score was 36, and the weekly averaged Peak Pruritus NRS was 8 on a 
> scale of 0-10. Overall, 92% of subjects had at least one co-morbid allergic condition; 66% had 
> allergic rhinitis, 54% had asthma, and 61% had food allergies.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 40, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=40)

> “Table 20: 
> Efficacy Results of DUPIXENT in AD-1526 at Week 16 (FAS)<sup>a</sup> in Pediatric 
> Subjects 12 Years of Age and Older with Moderate-to-Severe AD 
>
> DUPIXENT<sup>d</sup> 
> 200 mg (<60 kg) or 300 mg (≥60 kg) Q2W 
> N=82<sup>a</sup> 
> Placebo 
> N=85<sup>a</sup> 
> IGA 0 or 1<sup>b,c</sup> 
> 24% 
> 2% 
> EASI-75<sup>c</sup> 
> 42% 
> 8% 
> EASI-90<sup>c</sup> 
> 23% 
> 2% 
> Peak Pruritus NRS (≥4-point improvement)<sup>c</sup> 
> 37% 
> 5% 
> <sup>a</sup> Full Analysis Set (FAS) includes all subjects randomized. 
> <sup>b</sup> Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”) and a reduction of ≥2 points on 
> a 0-4 IGA scale. 
> <sup>c</sup> Subjects who received rescue treatment or with missing data were considered as non-responders (59% and 21% in 
> the placebo and DUPIXENT arms, respectively). 
> <sup>d</sup> At Week 0, subjects received 400 mg (baseline weight <60 kg) or 600 mg (baseline weight ≥60 kg) of 
> DUPIXENT.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 40, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=40)

<a id="dupixent-children-ad1652"></a>

### How effective is Dupixent in children aged 6 to 11 with severe atopic dermatitis (AD-1652)?

> “The efficacy and safety of DUPIXENT use concomitantly with TCS in pediatric subjects was 
> evaluated in a multicenter, randomized, double-blind, placebo-controlled trial (AD-1652; 
> NCT03345914) in 367 subjects 6 to 11 years of age, with AD defined by an IGA score of 
> 4 (scale of 0 to 4), an EASI score ≥21 (scale of 0 to 72), and a minimum BSA involvement of 
> ≥15%. Eligible subjects enrolled into this trial had previous inadequate response to topical 
> medication. Enrollment was stratified by baseline weight (<30 kg; ≥30 kg).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 41, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=41)

> “Table 21 presents the results by baseline weight strata for the approved dose regimens.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 42, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=42)

> “Table 21: 
> Efficacy Results of DUPIXENT with Concomitant TCS in AD-1652 at Week 
> 16 (FAS)<sup>a</sup> in Pediatric Subjects 6 to 11 Years of Age with AD 
>
> DUPIXENT  
> 300 mg Q4W<sup>d</sup> 
> + TCS 
> (N=61) 
> Placebo  
> + TCS 
>
> (N=61) 
> DUPIXENT  
> 200 mg Q2W<sup>e</sup> 
> + TCS 
> (N=59) 
> Placebo  
> + TCS 
>
> (N=62) 
> <30 kg 
> <30 kg 
> ≥30 kg 
> ≥30 kg 
> IGA 0 or 1<sup>b,c</sup> 
> 30% 
> 13% 
> 39% 
> 10% 
> EASI-75<sup>c</sup> 
> 75% 
> 28% 
> 75% 
> 26% 
> EASI-90<sup>c</sup> 
> 46% 
> 7% 
> 36% 
> 8% 
> Peak Pruritus NRS (≥4-point improvement)<sup>c</sup> 
> 54% 
> 12% 
> 61% 
> 13% 
> <sup>a</sup> Full Analysis Set (FAS) includes all subjects randomized. 
> <sup>b</sup> Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”). 
> <sup>c</sup> Subjects who received rescue treatment or with missing data were considered as non-responders. 
> <sup>d</sup> At Day 1, subjects received 600 mg of DUPIXENT. 
> <sup>e</sup> At Day 1, subjects received 200 mg (baseline weight <30 kg) or 400 mg (baseline weight ≥30 kg) of DUPIXENT.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 42, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=42)

<a id="dupixent-infants-ad1539"></a>

### How effective is Dupixent for atopic dermatitis in children 6 months to 5 years (AD-1539)?

> “The efficacy and safety of DUPIXENT use concomitantly with TCS in pediatric subjects was 
> evaluated in a multicenter, randomized, double-blind, placebo-controlled trial (AD-1539; 
> NCT03346434) in 162 subjects 6 months to 5 years of age, with moderate-to-severe AD defined 
> by an IGA score ≥3 (scale of 0 to 4), an EASI score ≥16 (scale of 0 to 72), and a minimum BSA 
> involvement of ≥10%. Eligible subjects enrolled into this trial had previous inadequate response 
> to topical medication. Enrollment was stratified by baseline weight (≥5 to <15 kg and ≥15 to 
> <30 kg).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 43, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=43)

> “Table 22: 
> Efficacy Results of DUPIXENT with Concomitant TCS in AD-1539 at Week 
> 16 (FAS)<sup>a</sup> in Pediatric Subjects 6 Months to 5 Years of Age with Moderate-
> to-Severe AD 
>
> DUPIXENT 
> + TCS 
> 200 mg (5 to <15 kg) or 
> 300 mg (15 to <30 kg) 
> Q4W<sup>d</sup> 
> (N=83)<sup>a</sup> 
> Placebo  
> + TCS 
>
>
>
> (N=79)<sup>a</sup> 
> Difference vs. Placebo (95 % CI) 
> IGA 0 or 1<sup>b,c</sup> 
> 28% 
> 4% 
> 24% (13%, 34%) 
> EASI-75<sup>c</sup> 
> 53% 
> 11% 
> 42% (29%, 55%) 
> EASI-90<sup>c</sup> 
> 25% 
> 3% 
> 23% (12%, 33%) 
> Worst Scratch/Itch NRS (≥4-point 
> improvement)<sup>c</sup> 
> 48% 
> 9% 
> 39% (26%, 52%) 
> CI = confidence interval 
> <sup>a</sup> Full Analysis Set (FAS) includes all subjects randomized. 
> <sup>b</sup> Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”). 
> <sup>c</sup> Subjects who received rescue treatment (63% and 19% in the placebo and DUPIXENT arms, respectively) or with 
> missing data were considered as non-responders.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 43, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=43)

> “<sup>d</sup> At Day 1, subjects received 200 mg (5 to <15 kg) or 300 mg (15 to <30 kg) of DUPIXENT.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 44, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=44)

<a id="dupixent-pediatric-long-term"></a>

### How was Dupixent studied long term in children with atopic dermatitis (AD-1434)?

> “AD-1434 STUDY DESIGN: Ongoing phase 3 open-label extension study in patients aged ≥6 months to <18 years with moderate-to-severe AD who participated in a DUPIXENT parent study. Data reflect exposure for 180 infants to preschoolers (aged 6 months to 5 years) and 383 children (aged 6-11 years). A total of 103 infants to preschoolers and 247 children completed 152 weeks of treatment. 1.7% of participants aged 6 months-5 years and 0.8% of participants aged 6-11 years discontinued due to treatment-emergent adverse reactions. Data presented are as observed<sup>5-7</sup>:
>
> Infants to preschoolers received DUPIXENT 200 mg Q4W (patients weighing 5 to <15 kg) or 300 mg Q4W (patients weighing 15 to <30 kg)
> Children received DUPIXENT 300 mg Q4W or were uptitrated to 200 mg Q2W (patients weighing 30 to <60 kg) or 300 mg Q2W (patients weighing ≥60 kg)
> Concomitant use of topical AD treatments (low-potency TCS, TCI, etc) was allowed”

Source: [DUPIXENT: Pediatric Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-skin-clearance-data#:~:text=AD%2D1434%20STUDY%20DESIGN%3A%20Ongoing%20phase,TCS%2C%20TCI%2C%20etc%29%20was%20allowed)

> “Limitation of analysis: Due to the open-label extension study design, results should be interpreted with consideration of potential selection bias.”

Source: [DUPIXENT: Pediatric Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-skin-clearance-data#:~:text=Limitation%20of%20analysis%3A%20Due%20to,consideration%20of%20potential%20selection%20bias.)

Note: The page presents EASI-75 and EASI-90 results through Week 152 as charts; those values are not quoted here.

## Hands and feet

<a id="dupixent-hand-foot-efficacy"></a>

### How effective is Dupixent for hand and foot atopic dermatitis (AD-HAFT)?

> “AD-HAFT enrolled adult and adolescent patients (12-17 years). In this trial, disease severity at baseline was defined by an IGA hand and foot score of ≥3 on a severity scale of 0 (clear) to 4 (severe). Participants included subjects with both hand and foot involvement (n=71), foot-only involvement (n=4), and hand-only involvement (n=58). At baseline, 72% of subjects had an IGA hand and foot score of 3 (moderate) and 28% had an IGA hand and foot score of 4 (severe); weekly average hand and foot Peak Pruritus NRS was 7.1 on a scale of 0 to 10; and mean HECSI score was 46.8 on a scale of 0 to 360.<sup>1,8</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Efficacy Results for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety#:~:text=AD%2DHAFT%20enrolled%20adult%20and%20adolescent,46.8%20on%20a%20scale%20of%200%20to)

> “Table 23: 
> Efficacy Results of DUPIXENT in Liberty-AD-HAFT at Week 16 (FAS)<sup>a</sup> in 
> Adult and Pediatric Subjects 12 Years of Age and Older with AD with 
> Moderate-to-Severe Hand and/or Foot Involvement 
>
> DUPIXENT 
> 200/300 mg Q2W<sup>d</sup> 
> (N=67)<sup>a</sup> 
> Placebo 
>
> (N=66)<sup>a</sup> 
> Difference vs. Placebo (95 % CI) 
> IGA (hand and foot) 0 or 1<sup>b,c</sup> 
> 40% 
> 17% 
> 24% (9%, 38%) 
> Improvement (reduction) of 
> weekly averaged hand and foot 
> Peak Pruritus NRS ≥4<sup>c</sup> 
> 52% 
> 14% 
> 39% (24%, 53%) 
> CI = confidence interval 
> <sup>a</sup> Full Analysis Set (FAS) includes all subjects randomized. 
> <sup>b</sup> Responder was defined as a subject with an IGA 0 or 1 (“clear” or “almost clear”). 
> <sup>c</sup> Subjects who received rescue treatment (21% and 3% in the placebo and DUPIXENT arms, respectively) or with 
> missing data were considered as non-responders.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 44, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=44)

> “<sup>d</sup> Adults received a loading dose of DUPIXENT 600 mg SC followed by 300 mg SC Q2W. Pediatric subjects 12 to 
> 17 years of age received a loading dose of DUPIXENT 600 mg SC followed by 300 mg SC Q2W (for body weight 
> ≥60 kg) or a loading dose of DUPIXENT 400 mg SC followed by 200 mg SC Q2W (for body weight <60 kg).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 45, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=45)

> “47% of DUPIXENT patients achieved ≥75% improvement from baseline in hand lesion extent and severity (HECSI-75) vs 22% with placebo at Week 16 (P<0.05; secondary endpoint)<sup>3</sup>”

Source: [DUPIXENT: AD HAFT Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/haft-skin-clearance-data#:~:text=47%25%20of%20DUPIXENT%20patients%20achieved,at%20Week%2016%20%28P%3C0.05%3B%20secondary)

> “All DUPIXENT-treated patients in AD-HAFT received DUPIXENT monotherapy for their hand and/or foot lesions<sup>3</sup>”

Source: [DUPIXENT: AD HAFT Skin Clearance Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/haft-skin-clearance-data#:~:text=All%20DUPIXENT%2Dtreated%20patients%20in%20AD%2DHAFT,for%20their%20hand%20and%2For%20foot)

<a id="dupixent-hand-foot-safety"></a>

### What was the safety of Dupixent for hand and foot atopic dermatitis (AD-HAFT)?

> “The safety profile of DUPIXENT in AD-HAFT through Week 16 was consistent with the safety profile seen in prior studies<sup>1</sup>”

Source: [DUPIXENT: AD HAFT Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/haft-safety-clinical-trial#:~:text=The%20safety%20profile%20of%20DUPIXENT,safety%20profile%20seen%20in%20prior)

> “The safety of DUPIXENT was assessed in a 16-week, multicenter, randomized, double-blind, 
> parallel-group, placebo-controlled trial (Liberty-AD-HAFT) in 133 adult and pediatric subjects 
> 12 to 17 years of age with atopic dermatitis with moderate-to-severe hand and/or foot 
> involvement [see Clinical Studies (14)]. In this trial 67 subjects received DUPIXENT, and 
> 66 subjects received placebo. DUPIXENT-treated subjects received the recommended dosage 
> based on their age and body weight [see Dosage and Administration (2.3)]. The safety profile of 
> DUPIXENT in these subjects through Week 16 was consistent with the safety profile from 
> studies in adult and pediatric subjects 6 months of age and older with moderate-to-severe AD.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 15, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=15)

## Skin of color

<a id="dupixent-skin-of-color"></a>

### How well does Dupixent work for atopic dermatitis in skin of color (DISCOVER)?

> “EASI-75 AT WEEK 24
> (primary endpoint)<sup>1</sup>”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=EASI%2D75%20AT%20WEEK%2024,%28primary)

> “76%
> DUPIXENT 200/300 mg Q2W (N=120)”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=76%25,DUPIXENT%20200%2F300%20mg%20Q2W%20%28N%3D120%29)

> “Itch response observed at Week 24<sup>1</sup>
>
> 66% of patients had ≥3-point improvement in Peak Pruritus NRS (secondary endpoint) 
> 53% of patients had ≥4-point improvement in Peak Pruritus NRS (secondary endpoint)”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=Itch%20response%20observed%20at%20Week,%E2%89%A54%2Dpoint%20improvement%20in%20Peak%20Pruritus%20NRS%20%28secondary%20endpoint%29)

> “DISCOVER Study: DISCOVER was a phase 4, open-label, single-arm, 24-week study to further evaluate the efficacy and safety of DUPIXENT monotherapy 200/300 mg Q2W in adolescent and adult patients with skin of color and moderate-to-severe AD (N=120). All DUPIXENT-treated adults and adolescents ≥60 kg received 300 mg Q2W after a 600 mg loading dose and patients ≥30 to <60 kg received 200 mg Q2W after a 400 mg loading dose. EASI-75 was the primary endpoint and secondary endpoints included ≥3-point and ≥4-point improvement in Peak Pruritus NRS.
> Limitations of analysis: Results may be subject to limitations such as open-label study design and lack of a placebo control group.<sup>1</sup>”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=DISCOVER%20Study%3A%20DISCOVER%20was%20a,lack%20of%20a%20placebo%20control)

> “Skin of color was defined as Fitzpatrick skin types IV, V, or VI. Patients self-reporting as White/Caucasian were ineligible.”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=Skin%20of%20color%20was%20defined,self%2Dreporting%20as%20White%2FCaucasian%20were%20ineligible.)

<a id="dupixent-hyperpigmentation"></a>

### Does Dupixent reduce postinflammatory hyperpigmentation in patients with skin of color?

> “PHSS TOTAL SCORE IMPROVEMENT AT WEEK 24
> (exploratory endpoint)<sup>2</sup>”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=PHSS%20TOTAL%20SCORE%20IMPROVEMENT%20AT,%28exploratory)

> “74%
> 61%
> 39%
> ≥2-point improvement (n=98)
> ≥3-point improvement (n=94)
> ≥4-point improvement (n=80)”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=74%25,%E2%89%A54%2Dpoint%20improvement%20%28n%3D80%29)

> “There was a 53% mean change in PHSS score from baseline to Week 24<sup>1</sup> 
> PHSS baseline: 5.1<sup>1</sup>”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=There%20was%20a%2053%25%20mean,PHSS%20baseline%3A)

> “Thresholds for clinically meaningful changes in PHSS scores have not been established.”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=Thresholds%20for%20clinically%20meaningful%20changes%20in%20PHSS%20scores%20have%20not%20been%20established.)

> “PHSS, the Postinflammatory Hyperpigmentation Severity Scale, is a clinician-rated tool assessing overall dyspigmentation severity (range: 0-8), based on<sup>1,2</sup>:
>
> Overall pigmentary change (range: 0-8)
> Area of hyperpigmented lesions (range: 0-5)
> Pigmentary intensity of hyperpigmented lesions (range: 0-5)
> Degree of hypopigmentation (range: 0-5)
> Presence/extent of erythema, burning, peeling dryness (range: 0-5)”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=PHSS%2C%20the%20Postinflammatory%20Hyperpigmentation%20Severity,burning%2C%20peeling%20dryness%20%28range%3A%200%2D5%29)

On the page, select: What is PHSS?

> “Limitations of analysis: Results may be subject to limitations such as open-label study design and lack of a placebo control group.<sup>1</sup>”

Source: [DUPIXENT: Results for Patients with Skin of Color, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/skin-of-color/results#:~:text=Limitations%20of%20analysis%3A%20Results%20may,lack%20of%20a%20placebo%20control)

## Outcome measures

<a id="dupixent-itch-measurement"></a>

### How was itch measured in the Dupixent atopic dermatitis trials?

> “In DUPIXENT pivotal clinical trials in AD, itch was measured using a 0- to 10-point numerical rating scale (NRS) assessing a patient’s worst itch over the previous 24 hours.”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=In%20DUPIXENT%20pivotal%20clinical%20trials,over%20the%20previous%2024%20hours.)

On the page, select: How was itch evaluated in DUPIXENT clinical trials?

> “Worst Scratch/Itch NRS asks caregivers of children aged 6 months to 5 years: "On a scale of 0 to 10, how would you rate the scratching/itching of the child you are a caregiver for at its worst during the previous 24 hours?"”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=Worst%20Scratch%2FItch%20NRS%20asks%20caregivers,during%20the%20previous%2024%20hours%3F%22)

On the page, select: How was itch evaluated in DUPIXENT clinical trials?

> “A reduction of ≥4 points from baseline is a clinically meaningful change.<sup>1</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=A%20reduction%20of%20%E2%89%A54%20points%20from%20baseline%20is%20a%20clinically%20meaningful)

On the page, select: How was itch evaluated in DUPIXENT clinical trials?

<a id="dupixent-easi-iga"></a>

### How were EASI and IGA scored in the Dupixent atopic dermatitis trials?

> “The Eczema Area and Severity Index (EASI) combines the severity of eczema signs and the extent of skin involvement to measure lesional signs of AD.<sup>9</sup>
>
> The severity of each of 4 eczema signs is assessed on a scale of 0 to 3<sup>9</sup>
>
> The signs of eczema (erythema, edema/papulation, excoriation, and lichenification) are graded using a defined process by the extent to which the patient is affected
>
> The extent of lesions in each body region is evaluated<sup>9</sup>
>
> The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6
> Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least
>
> Each region gets a total region score<sup>9</sup>:
>
> Severity Score x Area Score x Multiplier = Region Score 
>
> The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.<sup>9,a</sup>
>
> An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is a clinically meaningful change.<sup>1</sup>
>
> <sup>a</sup>
> In patients <8 years of age, the multipliers for the head and neck are 0.2, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.3. In patients ≥8 years of age, the multipliers for the head and neck are 0.1, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.4.<sup>9</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=The%20Eczema%20Area%20and%20Severity,the%20upper%20extremities%20are%200.2%2C%20and%20the%20lower%20extremities%20are)

On the page, select: How was extent and severity of skin lesions (EASI) assessed in DUPIXENT clinical trials?

> “Investigator's Global Assessment (IGA) for skin clearance assesses the overall severity of clinical signs of atopic dermatitis using a 0- to 4-point scoring system.<sup>2</sup>
>
> A clinical responder was defined as a patient achieving IGA 0 or 1 and, in adults and adolescents, ≥2-point improvement from baseline.<sup>1</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=Investigator%27s%20Global%20Assessment%20%28IGA%29%20for,and%20adolescents%2C%20%E2%89%A52%2Dpoint%20improvement%20from)

On the page, select: How was skin clearance (IGA) assessed in DUPIXENT clinical trials?

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Indication](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
